R-Pharm US

R-Pharm US is a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of therapies for oncology and inflammatory diseases. As a subsidiary of the R-Pharm Group, the company significantly expanded its portfolio in 2015 by acquiring the global rights to Ixempra (ixabepilone), a chemotherapy agent for metastatic breast cancer, from Bristol Myers Squibb. In addition to its commercial oncology business, R-Pharm US is advancing a clinical pipeline that includes goflikicept, an IL-1 trap for rare inflammatory conditions, and olokizumab, an IL-6 inhibitor for rheumatoid arthritis. The company leverages its expertise in clinical development and medical affairs to bring innovative treatments to the US market.